ExCellThera Announces First Patient Treated in Phase I/II Trial of ECT-001 Cell Therapy for Pediatric Patients with High Risk Blood Cancer

ExCellThera Inc. announced that the first patient has been dosed in its Phase I/II clinical trial of ECT-001 for the treatment of pediatric and young adults with high risk myeloid malignancies.